Verix Elevates Graham Kantor to Principal After Industrial Push

Verix Equity Partners, a lower-middle-market private equity firm managing $750 million focused on essential healthcare and industrial services, has promoted Graham Kantor to Principal after four years with the firm. The move comes as Verix's portfolio companies have collectively added more than $500 million in revenue since 2021 through a combination of organic growth and strategic acquisitions.

Kantor joined Verix in 2022 as a Vice President and has been involved in multiple platform investments and add-on acquisitions across the firm's core sectors. His promotion reflects the firm's strategy of building deal teams internally rather than recruiting laterally — a deliberate approach in an industry where talent poaching has become routine.

Before Verix, Kantor spent three years at Gridiron Capital, another middle-market firm, where he worked on investments in industrial distribution and business services. He started his private equity career at Lincoln International's valuation and opinions group, giving him exposure to deal structures before moving to the principal side.

The firm didn't disclose which specific deals Kantor led, but Verix's recent activity offers clues. Since 2021, the firm has backed companies in healthcare IT, diagnostic services, industrial equipment maintenance, and specialty logistics — all sectors where fragmentation creates roll-up opportunities and where essential service models generate predictable cash flow even during downturns.

Verix was founded in 2020 by veterans from Chicago-based private equity firms, including GTCR and Wind Point Partners. The firm's thesis centers on companies that provide critical services in fragmented markets — think HVAC maintenance contractors serving hospitals, or software platforms managing medical billing for regional health systems.

The $750 million under management figure positions Verix squarely in the lower-middle-market segment, where deal sizes typically range from $50 million to $250 million in enterprise value. That puts the firm in competition with other healthcare-focused shops like Shore Capital Partners, LLR Partners, and Southgate Capital, all of whom have been active in similar sectors.

What distinguishes Verix's approach is its willingness to back industrial services companies that serve healthcare end markets — a hybrid strategy that lets the firm participate in healthcare's defensive characteristics without being confined to pure-play medical businesses. One portfolio company might manufacture cleanroom equipment for pharmaceutical facilities; another might handle waste management for surgical centers.

This cross-sector positioning has proven useful as healthcare M&A activity has fragmented. Pure-play healthcare services deals faced pricing pressure in 2024 and 2025 as interest rates stayed elevated and strategic buyers pulled back. Industrial services companies with healthcare exposure, meanwhile, continued to trade at reasonable multiples because they weren't competing with the same crowded buyer pool.

Verix's claim of $500 million-plus in portfolio revenue growth since 2021 is notable, but it requires context. The firm hasn't disclosed how many platform companies it owns or what the revenue base was in 2021, making it impossible to calculate organic growth rates versus acquisition-driven expansion.

If Verix deployed $750 million across, say, eight to ten platforms at an average 6x EBITDA multiple — typical for lower-middle-market services businesses — that would imply roughly $125 million in aggregate EBITDA at entry. Assuming 20-25% EBITDA margins (standard for asset-light service companies), that suggests an initial revenue base of $500 million to $625 million.

Adding $500 million in revenue on top of that base would represent roughly 80-100% growth over four years, or about 15-20% compounded annually. That's aggressive for organic growth alone, which suggests the firm has been executing add-on acquisitions at a steady clip — likely two to four bolt-ons per platform company.

These are rough estimates, but they align with typical buy-and-build strategies in fragmented service sectors. The real question is whether that growth was achieved efficiently — meaning, did Verix pay reasonable multiples for add-ons, or did acquisition costs creep up as competition for targets intensified?

One challenge facing roll-up strategies in 2025 and 2026 has been the persistence of elevated add-on pricing. Sellers of $5 million to $20 million EBITDA businesses have become more sophisticated, often running dual-track processes or hiring investment bankers even for small deals. That's pushed purchase price multiples for bolt-ons closer to platform multiples, compressing the arbitrage that makes buy-and-build strategies accretive.

Internal promotions at PE firms are always partly about retention, but they also reflect strategic priorities. Elevating someone who has been with the firm through its first full investment cycle suggests Verix is focused on continuity and institutional knowledge rather than bringing in outside perspectives.

That's a bet on execution over pivot. If Verix were planning to move into new sectors or geographies, you'd expect to see lateral hires with different networks or expertise. Promoting from within means the firm believes its current playbook — healthcare and industrial services, buy-and-build, lower-middle-market focus — still has room to run.

It also suggests the firm is preparing for its next fundraise. Demonstrating a stable, growing investment team is critical when pitching limited partners, especially institutional investors who evaluate GP continuity as a risk factor. If Verix is targeting a second fund in the $1 billion to $1.5 billion range, having a Principal-level team member who has been with the firm since Fund I provides narrative continuity.

Kantor's educational background — he holds a bachelor's degree from the University of Michigan and an MBA from the University of Chicago Booth School of Business — fits the profile of a typical middle-market deal professional. Booth's private equity curriculum is heavily analytical, which aligns with Verix's emphasis on operational value creation rather than financial engineering.

The firm's leadership, including Managing Partners who previously worked at GTCR and Wind Point, brings decades of experience in healthcare and industrial buyouts. That institutional knowledge has likely shaped how Verix approaches diligence, value creation planning, and exit timing — all areas where first-time fund managers often stumble.

One underappreciated aspect of internal promotions is their signaling effect on junior team members. In an industry where Associates and VPs routinely leave for business school or competing firms, creating a visible path to Principal and Partner roles can improve retention. That matters in middle-market PE, where deal teams are small and losing a VP mid-transaction can derail timelines.

Verix's decision to announce this promotion publicly — via press release rather than a quiet internal memo — also suggests the firm is building its brand. Younger PE firms often struggle with visibility, especially when competing for deals against established names. Press mentions, even for personnel moves, help surface the firm's name in broker networks and intermediary databases.

The broader healthcare services M&A market has seen mixed activity in 2025 and 2026. High-quality assets — particularly those with recurring revenue, strong unit economics, and limited reimbursement risk — continue to attract aggressive bidding. Companies dependent on government payers or facing regulatory uncertainty have seen valuations compress.

Verix's focus on essential services positions it in the former category. HVAC contractors serving hospitals don't face reimbursement risk. Software platforms managing claims processing benefit from increasing administrative complexity in healthcare. Diagnostic equipment maintenance providers serve a need that exists regardless of payment model shifts.

That defensive positioning has become more attractive as macroeconomic uncertainty persists. While growth equity investors pulled back from speculative healthcare tech plays in 2024, buyout firms focused on essential services have maintained deal flow. The shift reflects a broader return to fundamentals — profitability, cash generation, and mission-critical services over rapid top-line growth.

One risk Verix faces is the potential for increased competition from larger firms moving downstream. As mega-funds struggle to deploy capital efficiently, some have started targeting smaller platforms with the intent to scale them aggressively. That can inflate entry multiples and make it harder for mid-sized firms to win auctions.

Verix operates in a crowded segment. Shore Capital Partners, based in Chicago, has built a reputation for healthcare and education roll-ups. LLR Partners, headquartered in Philadelphia, focuses on software and healthcare IT. Southgate Capital, in Charlotte, targets lower-middle-market healthcare services with a similar buy-and-build approach.

What differentiates these firms often comes down to operational capabilities rather than deal-sourcing. All have access to similar proprietary networks and intermediary relationships. The firms that generate superior returns tend to have in-house operating partners who can drive margin improvement, identify cost synergies, and execute post-merger integration plans efficiently.

Verix's smaller fund size means it can pursue deals that larger firms pass on due to minimum check size requirements. That's an advantage in auctions where the seller prioritizes speed and certainty over maximizing the last dollar of valuation. Smaller funds can also be more flexible on deal structure, offering earnouts or seller rollovers that appeal to founder-owned businesses.

The downside is limited dry powder for follow-on capital. If a portfolio company encounters an unexpected acquisition opportunity or needs balance sheet support during a downturn, smaller funds have less room to maneuver. That can force difficult decisions — bring in a co-investor and dilute ownership, or pass on an attractive add-on.

Kantor's new role will likely involve increased responsibility for deal sourcing, diligence leadership, and portfolio company oversight. At the Principal level, professionals typically take the lead on specific transactions while also mentoring junior team members and contributing to fundraising efforts.

For Verix, the next 12-24 months will be critical. If the firm is planning a second fund, it will need to demonstrate strong performance metrics from Fund I — ideally, at least one full or partial exit with a realized multiple of invested capital (MOIC) above 2.5x. The $500 million in revenue growth is a useful marketing point, but LPs care more about cash-on-cash returns and IRR.

The firm's ability to execute exits will depend partly on factors outside its control — M&A market liquidity, strategic buyer appetite, and the availability of debt financing for potential acquirers. But it will also depend on whether Verix's portfolio companies have genuinely improved their competitive positioning or simply grown through acquisition without operational integration.

That's the test every buy-and-build strategy eventually faces. Rolling up revenue is straightforward if capital is available and sellers are willing. Creating a platform that's worth more than the sum of its parts — through shared infrastructure, cross-selling, or genuine operational improvements — is harder.

Verix's personnel move happens against a backdrop of shifting dynamics in middle-market private equity. The sector has seen record fundraising over the past five years, creating intense competition for quality assets. At the same time, exit markets have been choppy, with IPO windows largely closed and strategic buyers more selective.

That combination — abundant capital chasing deals, limited exit opportunities — has compressed returns for many middle-market managers. The firms that have outperformed tend to share common traits: disciplined underwriting, strong operational value creation capabilities, and the patience to hold assets through market cycles rather than forcing exits at suboptimal times.

Whether Verix fits that profile will become clear over the next few years. For now, promoting a deal team member who has been with the firm since its early days suggests confidence in the strategy and continuity in execution. Whether that confidence is justified will depend on exits, not announcements.

And Kantor's promotion, while a milestone for him personally, is ultimately a signaling mechanism — to LPs, to portfolio company management teams, to intermediaries and co-investors. The message: Verix is building for the long term, investing in its people, and executing a strategy it believes still has room to run. The market will judge whether that message translates into returns.